Cargando…

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection

Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Victor Chien-Chia, Li, Yan-Rong, Wang, Chao-Yung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268177/ https://www.ncbi.nlm.nih.gov/pubmed/34281221 http://dx.doi.org/10.3390/ijms22137170

Ejemplares similares

Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
por: Prandi, Francesca Romana, et al.
Publicado: (2022)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Jing, Yuling, et al.
Publicado: (2022)

Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
por: Li, Xiaoling, et al.
Publicado: (2022)

Sodium glucose co transporter 2 inhibitors and Ramadan: Another string to the bow
por: Kelwade, Jayant, et al.
Publicado: (2014)

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
por: Singh, Awadhesh Kumar
Publicado: (2015)

Sodium glucose co-transporter-2 inhibitor: Patient safety and clinical importance
por: Senthilkumaran, Subramanian, et al.
Publicado: (2017)

Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
por: Seo, Ji A
Publicado: (2018)

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control
por: Baruah, Manash Pratim, et al.
Publicado: (2019)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter-2 Inhibitor-Induced Pruritus: Itching for Answers
por: Ali, Kabeer, et al.
Publicado: (2021)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage
por: Kourtidou, Christodoula, et al.
Publicado: (2023)

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
por: Lee, Hsiang-Chun, et al.
Publicado: (2019)

Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability
por: Chen, Yung‐Chih, et al.
Publicado: (2021)

Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?
por: Giorgino, Francesco, et al.
Publicado: (2020)

TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity
por: Wang, Chao-Yung, et al.
Publicado: (2020)

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
por: Shao, Shih-Chieh, et al.
Publicado: (2019)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Sodium glucose co-transporter inhibitors – A new class of old drugs
por: Malhotra, Aneeta, et al.
Publicado: (2015)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
por: Lahnwong, Sarayut, et al.
Publicado: (2018)

Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
por: Melnick, Stephen, et al.
Publicado: (2018)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
por: Ye, Yangli, et al.
Publicado: (2019)

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
por: Brito, Dulce, et al.
Publicado: (2020)

Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis
por: Suvarna, Viraj Ramesh
Publicado: (2021)

Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin
por: Ryan, Rebecca, et al.
Publicado: (2020)

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
por: Joshi, Shruti S, et al.
Publicado: (2021)

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors
por: Angelini, Gianmarco, et al.
Publicado: (2021)

Sodium‐glucose co‐transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction
por: Tiwary, Mansi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rr5sucm6c56dcr07sn5g8ut5r8